Metacrine, Inc. Common Stock
MTCR
MTCR was delisted on the 8th of February, 2023.
27 hedge funds and large institutions have $3.93M invested in Metacrine, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
28% more capital invested
Capital invested by funds: $3.06M → $3.93M (+$870K)
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
8% more funds holding
Funds holding: 25 → 27 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$845K |
| 2 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$172K |
| 3 |
Jane Street
New York
|
+$85.3K |
| 4 |
CL
CSS LLC
Chicago,
Illinois
|
+$83.3K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$67.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$99K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$95.4K |
| 3 |
CM
Crestline Management
Fort Worth,
Texas
|
-$79K |
| 4 |
VF
Virtu Financial
New York
|
-$14K |
| 5 |
Two Sigma Advisers
New York
|
-$12.5K |
MTCR Hedge Fund Activity: Q3 2022 in Review
27 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Metacrine, Inc. Common Stock (MTCR) for Q3 2022, worth a combined $3.93M — up 28% from $3.06M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new MTCR positions and 4 closed out — a net gain of 2 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $845K. The largest seller was Pura Vida Investments, exiting entirely with an estimated $99K sold.
- 27 institutional investors held Metacrine, Inc. Common Stock (MTCR) as of Q3 2022, up from 25 in Q2 2022.
- Funds reported $3.93M of Metacrine, Inc. Common Stock stock for Q3 2022, up 28% quarter-over-quarter.
- 6 funds opened new Metacrine, Inc. Common Stock positions in Q3 2022 and 4 closed out, a net change of +2 holders.
- The largest Metacrine, Inc. Common Stock buyer in Q3 2022 was Tang Capital Management, an estimated $845K added.
- The largest Metacrine, Inc. Common Stock seller in Q3 2022 was Pura Vida Investments, an estimated $99K sold.
Based on aggregated 13F filings for Q3 2022.